Display options
Cite
Masoodi M, Talebi-Taher M, Tabatabaie K, et al. Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East J Dig Dis. 2015;7(2):88-93
Masoodi, M., Talebi-Taher, M., Tabatabaie, K., Khaleghi, S., Faghihi, A. H., Agah, S., & Asadi, R. (2015). Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East journal of digestive diseases, 7(2), 88-93.
Masoodi, Mohsen, et al. "Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial." Middle East journal of digestive diseases vol. 7,2 (2015): 88-93.
Masoodi M, Talebi-Taher M, Tabatabaie K, Khaleghi S, Faghihi AH, Agah S, Asadi R. Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial. Middle East J Dig Dis. 2015 Apr;7(2):88-93. PMID: 26106468; PMCID: PMC4430797.
Copy Download .nbib Format: NLM
Share it on

Middle East J Dig Dis. 2015 Apr;7(2):88-93.

Clarithromycin vs. Gemifloxacin in Quadruple Therapy Regimens for Empiric Primary Treatment of Helicobacter pylori Infection: A Randomized Clinical Trial.

Middle East journal of digestive diseases

Mohsen Masoodi, Mahshid Talebi-Taher, Khadijeh Tabatabaie, Siamak Khaleghi, Amir-Hossein Faghihi, Shahram Agah, Reyhaneh Asadi

Affiliations

  1. Associate professor, Colorectal Research Center, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran.
  2. Associate professor, Antimicrobial Resistance Research Center, Infectious Diseases Department, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran.
  3. Researcher, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran.
  4. Assistant professor, Colorectal Research Center, Rasoul-e-Akram General Hospital, Iran University of Medical Sciences, Tehran, Iran.

PMID: 26106468 PMCID: PMC4430797

Abstract

BACKGROUND Eradication of Helicobacter pylori infection plays a crucial role in the treatment of peptic ulcer. Clarithromycin resistance is a major cause of treatment failure. This randomized clinical trial aimed at evaluating the efficacy of a clarithromycin versus gemifloxacin containing quadruple therapy regimen in eradication of H.pylori infection. METHODS In this randomized double blind clinical trial (RCT 2012102011054N2), a total of 120 patients were randomized to two groups of 60 patients each. Patients with proven H.pylori infection were consecutively assigned into two groups to receive OBAG or OBAC in gastroenterology clinic in Rasoul-e- Akram General Hospital in Tehran, Iran. The patients in the OBAG group received omeprazole (20 mg) twice daily, bismuth subcitrate (240 mg) twice daily, amoxicillin (1 gr) twice daily, and gemifloxacin (320 mg) once daily, and those in the OBAC group received omeprazole (20 mg) twice daily, 240 mg of bismuth subcitrate twice daily, amoxicillin (1 gr) twice daily, and clarithromycin (500 mg) twice daily for 10 days. RESULTS Five patients from each group were excluded from the study because of poor compliance, so 110 patients completed the study. The intention-to-treat eradication rate was 61.6% and 66.6% for the OBAC and OBAG groups, respectively. According to the per protocol analysis, the success rates of eradication of H.pylori infection were 67.2% and 72.7% for OBAC and OBAG groups, respectively (p=0.568). CONCLUSION The results of this study suggest that gemifloxacin containing regimen is at least as effective as clarithromycin regimen; hence, this new treatment could be considered as an alternative for the patients who cannot tolerate clarithromycin.

Keywords: Clarithromycin; Gemifloxacin; H.pylori; Iran

References

  1. Aliment Pharmacol Ther. 1999 Jun;13(6):775-80 - PubMed
  2. J Antimicrob Chemother. 2001 Mar;47(3):360-1 - PubMed
  3. Therap Adv Gastroenterol. 2011 Mar;4(2):103-14 - PubMed
  4. World J Gastroenterol. 2010 Dec 7;16(45):5746-51 - PubMed
  5. Helicobacter. 2012 Jun;17(3):210-5 - PubMed
  6. Nat Clin Pract Gastroenterol Hepatol. 2008 Jun;5(6):321-31 - PubMed
  7. Aliment Pharmacol Ther. 2001 Mar;15(3):411-6 - PubMed
  8. World J Gastroenterol. 2012 Dec 7;18(45):6628-34 - PubMed
  9. Intern Emerg Med. 2012 Oct;7(5):447-52 - PubMed
  10. Gut. 2004 Sep;53(9):1374-84 - PubMed
  11. World J Gastroenterol. 2014 Jan 21;20(3):665-72 - PubMed
  12. Gut. 2010 Nov;59(11):1465-70 - PubMed
  13. Indian J Gastroenterol. 2013 Nov;32(6):392-6 - PubMed
  14. Drugs Today (Barc). 2001 Jun;37(6):401-410 - PubMed
  15. Saudi J Gastroenterol. 2011 Jul-Aug;17(4):261-4 - PubMed
  16. J Antimicrob Chemother. 2002 Jun;49(6):1039-40 - PubMed
  17. Am J Gastroenterol. 2014 Apr;109(4):485-95 - PubMed
  18. J Microbiol. 2011 Dec;49(6):987-93 - PubMed
  19. J Antimicrob Chemother. 2000 Aug;46(2):283-5 - PubMed
  20. J Antimicrob Chemother. 2009 May;63(5):1017-24 - PubMed
  21. Nat Rev Gastroenterol Hepatol. 2014 Apr;11(4):234-42 - PubMed
  22. Z Gastroenterol. 2011 Aug;49(8):989-96 - PubMed
  23. Aliment Pharmacol Ther. 2007 Aug 1;26(3):495-500 - PubMed
  24. Helicobacter. 2003 Feb;8(1):80 - PubMed
  25. Helicobacter. 2005 Aug;10(4):360-1 - PubMed
  26. Helicobacter. 2010 Apr;15(2):154-9 - PubMed
  27. J Antimicrob Chemother. 2000 Dec;46(6):1029-31 - PubMed

Publication Types